Page last updated: 2024-08-21

quinazolines and Bare Lymphocyte Syndrome

quinazolines has been researched along with Bare Lymphocyte Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, WS; Chen, YJ; Hsia, TC; Hsu, SC; Huang, CY; Huang, TC; Huang, WC; Hung, MC; Tsai, SL; Tu, CY; Wei, YL; Yeh, MH; Yen, CJ; Yu, MC; Yu, YL	1

Other Studies

1 other study(ies) available for quinazolines and Bare Lymphocyte Syndrome

Article	Year
Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Molecular pharmacology, 2013, Volume: 83, Issue:4 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Severe Combined Immunodeficiency; Up-Regulation; Xenograft Model Antitumor Assays	2013

Article

Year

Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.

Molecular pharmacology, 2013, Volume: 83, Issue:4

Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Severe Combined Immunodeficiency; Up-Regulation; Xenograft Model Antitumor Assays

2013